MDG1011

MDG1011 is an autologous T cell receptor-engineered T cell (TCR-T) therapy developed for the treatment of high-risk blood cancers, specifically relapsed or refractory acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and multiple myeloma (MM)[1][4][5]. The therapy uses patient-derived CD8+ T cells that are genetically modified to express a recombinant T cell receptor specific for a peptide fragment of the tumor antigen PRAME (PReferentially expressed Antigen in MElanoma), which is presented on cancer cells by HLA-A*02:01 molecules[4][5][6]. Upon administration, these engineered T cells target and bind to PRAME-expressing tumor cells, leading to their destruction through immune-mediated cytotoxicity[2][5]. MDG1011 has demonstrated safety, tolerability, and preliminary signs of clinical activity in Phase I trials involving heavily pretreated patients with advanced-stage hematologic malignancies[3][4].

Other names

autologous PRAME-targeting TCR-modified T cells